![Iain Dukes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Iain Dukes
Vorstandsvorsitzender bei
TRAWS PHARMA, INC.
Vermögen: 340 926 $ am 31.05.2026
Profil
Dr. Iain D. Dukes ist Chief Executive Officer bei Viriom, Inc, President & Director bei Kartos Therapeutics, Inc, Independent Director bei Ikena Oncology, Inc, Venture Partner bei OrbiMed Advisors Private Equity, Chairman bei Iovance Biotherapeutics, Inc, Executive Chairman bei Theseus Pharmaceuticals, Inc, President bei Telios Pharmaceuticals, Inc. und President & Chief Executive Officer bei Arrys Therapeutics, Inc. Er ist Mitglied des Board of Directors von Angiex, Inc, ENYO Pharma SA, Kartos Therapeutics, Inc, Ikena Oncology, Inc, NeRRe Therapeutics Holdings Ltd, NeRRe Therapeutics Ltd. und ReViral Ltd. Dr. Dukes war zuvor als Mitglied des Aufsichtsrates bei Themis Bioscience GmbH, als SVP & Head-Business Development bei Merck Research Laboratories Massachusetts LLC, als VP-External Research & Development bei Amgen, Inc, ein President & Chief Executive Officer von Essentialis, Inc. ein VP-Scientific and Technology Licensing von GlaxoSmithKline, Inc. ein Head-Exploratory Development von Glaxo Wellcome, Inc. ein Principal von Glaxo, Inc. und ein Senior VP-Business Development & Licensing von Merck & Co, Inc. Er war auch im Vorstand von KaNDy Therapeutics Ltd. Er erhielt seinen Bachelor-Abschluss an der University of Bath, einen Bachelor-Abschluss an der University of Oxford, einen Master-Abschluss an der University of Leeds und einen Doktortitel an der University of Oxford.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.04.2026 | 54’000 ( 0.01% ) | 221 400 $ | 31.05.2026 | |
TRAWS PHARMA, INC. 0.54% | 01.05.2026 | 81’867 ( 0.54% ) | 119 526 $ | 31.05.2026 |
Aktive Positionen von Iain Dukes
| Unternehmen | Position | Beginn |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Vorsitzender | 16.08.2016 |
| TRAWS PHARMA, INC. | Vorstandsvorsitzender | 31.03.2025 |
Telios Pharmaceuticals, Inc.
 Telios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pharmaceuticals, research | Gründer | - |
NeRRe Therapeutics Holdings Ltd.
 NeRRe Therapeutics Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology | Direktor/Vorstandsmitglied | 08.09.2017 |
Trawsfynydd Therapeutics, Inc.
 Trawsfynydd Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovering and developing antiviral medicines | Gründer | 01.01.2021 |
Feldan Bio, Inc.
 Feldan Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops, produces and supplies recombinant proteins for therapeutic and research purposes | Direktor/Vorstandsmitglied | - |
Lomond Therapeutics, Inc.
 Lomond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company for treating hematological cancers | Vorstandsvorsitzender | - |
Venetian-1 Acquisition Corp.
 Venetian-1 Acquisition Corp. Pharmaceuticals: MajorHealth Technology Develops medicines for hematological malignancies | Vorstandsvorsitzender | 01.11.2024 |
Viriom, Inc.
 Viriom, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Vorstandsvorsitzender | 01.02.2019 |
Ehemalige bekannte Positionen von Iain Dukes
| Unternehmen | Position | Ende |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░ | - |
| ░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Iain Dukes
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
55
Beziehungen ersten Grades
33
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 33 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Telios Pharmaceuticals, Inc.
Telios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pharmaceuticals, research | Health Technology |
Traws Pharma, Inc.
 Traws Pharma, Inc. BiotechnologyHealth Technology Discovers and develops products for patients with cancer | Health Technology |
University of Bath
 University of Bath Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Leeds
 University of Leeds Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
GlaxoSmithKline, Inc.
 GlaxoSmithKline, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity invests in companies located across the globe primarily in North America, Asia, Europe and Israel. The firm focuses on biopharmaceuticals, medical technology and healthcare services. It participates in seed-stage, early stage, growth transactions. It also provides debt capital and monetize royalty streams and invests in publicly-traded companies. | Finance |
Essentialis, Inc.
 Essentialis, Inc. Pharmaceuticals: OtherHealth Technology Develops therapeutic products in curing metabolic diseases | Health Technology |
Glaxo Wellcome, Inc.
 Glaxo Wellcome, Inc. Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical preparations | Health Technology |
Glaxo, Inc. | |
Themis Bioscience GmbH
 Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops vaccines to prevent infectious diseases | Health Technology |
Iovance Biotherapeutics, Inc.
 Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
BITOECH Consulting SAS
 BITOECH Consulting SAS Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Commercial Services |
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services Provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity | Distribution Services |
Feldan Bio, Inc.
Feldan Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops, produces and supplies recombinant proteins for therapeutic and research purposes | Health Technology |
ENYO Pharma SA
 ENYO Pharma SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology Develops novel antiviral therapeutics | Health Technology |
Ikena Oncology, Inc.
 Ikena Oncology, Inc. BiotechnologyHealth Technology Develops metabolic enzymes based immunotherapy for oncology applications | Health Technology |
Angiex, Inc.
 Angiex, Inc. Miscellaneous Commercial ServicesCommercial Services Develops vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis | Commercial Services |
KaNDy Therapeutics Ltd.
 KaNDy Therapeutics Ltd. BiotechnologyHealth Technology Develops medicines for female sex hormone disorders | Health Technology |
Arrys Therapeutics, Inc.
 Arrys Therapeutics, Inc. Hospital/Nursing ManagementHealth Services Provides treatments to cancer patients | Health Services |
Theseus Pharmaceuticals, Inc.
 Theseus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and supplies drugs for cancer patients | Health Technology |
Kartos Therapeutics, Inc.
 Kartos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical stage biopharmaceutical company | Health Technology |
Viriom, Inc.
Viriom, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company | Commercial Services |
NeRRe Therapeutics Holdings Ltd.
NeRRe Therapeutics Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology | Commercial Services |
Lomond Therapeutics, Inc.
Lomond Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company for treating hematological cancers | Health Technology |
Gwynant Therapeutics
 Gwynant Therapeutics Pharmaceuticals: MajorHealth Technology Develops novel small molecules for oncology targets | Health Technology |
Venetian-1 Acquisition Corp.
Venetian-1 Acquisition Corp. Pharmaceuticals: MajorHealth Technology Develops medicines for hematological malignancies | Health Technology |
Trawsfynydd Therapeutics, Inc.
Trawsfynydd Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in discovering and developing antiviral medicines | Commercial Services |
Eilean Therapeutics LLC
 Eilean Therapeutics LLC Pharmaceuticals: MajorHealth Technology Engages in discovery and development of small molecule inhibitors therapies for hematological cancers | Health Technology |
